Literature DB >> 19536817

Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes.

Elisa Pasini1, Laura Caggiari, Luigino Dal Maso, Debora Martorelli, Massimo Guidoboni, Emanuela Vaccher, Luigi Barzan, Giovanni Franchin, Annunziata Gloghini, Valli De Re, Nicoletta Sacchi, Diego Serraino, Antonino Carbone, Antonio Rosato, Riccardo Dolcetti.   

Abstract

The role of genetic factors involved in the development of undifferentiated nasopharyngeal carcinoma (UNPC) in nonendemic areas has been poorly investigated. High-resolution human leukocyte antigen (HLA) class I genotyping carried out in 82 Italian UNPC patients and 286 bone marrow donors born in the same province showed that A*0201, B*1801, and B*3501, known to efficiently present Epstein-Barr virus (EBV)-derived epitopes, were significantly under-represented in UNPC patients. Moreover, the A*0201/B*1801 haplotype was significantly less frequent in UNPC cases, with a 90% reduced risk (odds ratio [OR] 0.1, 95% confidence interval [CI] = 0.0-0.5) to develop UNPC, suggesting an additive effect. Notably, all 5 BARF1 epitopes and 7 of the 8 LMP-2 epitopes known to bind A*0201 showed a fully conserved sequence in all the 31 Italian EBV isolates investigated. The 4 amino acid changes affecting the 436-447 LMP-2 epitope do not reduce, but rather increase in two cases, the predicted ability of "variant" epitopes to bind the HLA-A*0201 allele, as shown by immunoinformatic analysis. Moreover, a significantly increased risk for UNPC was associated with A*2601 (OR 2.4, 95% CI = 1.1-4.9) and B*4101 (OR 9.2, 95% CI = 2.5-34.3). These findings indicate that Italian UNPC patients have a distinct HLA-A and -B genotypic profile and suggest that the decreased risk for UNPC conferred by definite HLA class I molecules is probably related to their ability to efficiently present LMP-2 and BARF1 epitopes that are highly conserved in EBV isolates from this geographic region. These results have practical implications for the immunotherapy of UNPC. 2009 UICC

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536817     DOI: 10.1002/ijc.24515

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Prognostic significance of clinical parameters and Epstein-Barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: a Serbian report.

Authors:  T T Terzic; M I Boricic; I P Pendjer; D T Ruzic Zecevic; N R Tomanovic; D C Brasanac; I V Boricic
Journal:  Med Oncol       Date:  2010-05-06       Impact factor: 3.064

2.  HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China.

Authors:  Xin Huang; Bouke Hepkema; Ilja Nolte; Kushi Kushekhar; Theo Jongsma; Rianne Veenstra; Sibrand Poppema; Zifen Gao; Lydia Visser; Arjan Diepstra; Anke van den Berg
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 3.  BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Authors:  Eveline K Hoebe; Tessa Y S Le Large; Astrid E Greijer; Jaap M Middeldorp
Journal:  Rev Med Virol       Date:  2013-08-31       Impact factor: 6.989

4.  A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Authors:  Riccardo Turrini; Anna Merlo; Debora Martorelli; Damiana Antonia Faè; Roberta Sommaggio; Isabella Monia Montagner; Vito Barbieri; Oriano Marin; Paola Zanovello; Riccardo Dolcetti; Antonio Rosato
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

5.  Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.

Authors:  Octavia Ramayanti; Sandra A W M Verkuijlen; Putri Novianti; Chantal Scheepbouwer; Branislav Misovic; Danijela Koppers-Lalic; Jan van Weering; Lisa Beckers; Marlinda Adham; Debora Martorelli; Jaap M Middeldorp; Dirk Michiel Pegtel
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

6.  DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas.

Authors:  Xizhou Zhu; Alfredo Perales-Puchalt; Krzysztof Wojtak; Ziyang Xu; Kun Yun; Pratik S Bhojnagarwala; Devivasha Bordoloi; Daniel H Park; Kevin Liaw; Mamadou A Bah; Paul M Lieberman; Ebony N Gary; Ami Patel; David B Weiner
Journal:  Mol Ther Oncolytics       Date:  2021-12-21       Impact factor: 6.311

7.  Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients.

Authors:  Dimitrios Krikelis; Mattheos Bobos; Georgia Karayannopoulou; Liliana Resiga; Sofia Chrysafi; Epaminontas Samantas; Dimitrios Andreopoulos; Vassilios Vassiliou; Elisabeta Ciuleanu; George Fountzilas
Journal:  BMC Clin Pathol       Date:  2013-01-29

8.  An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors.

Authors:  Vittorio Perfetti; Mattia Ricotti; Franco Buonaguro; Umberto Tirelli; Paolo Pedrazzoli
Journal:  Infect Agent Cancer       Date:  2012-09-05       Impact factor: 2.965

9.  Sequence analysis of Epstein-Barr virus (EBV) early genes BARF1 and BHRF1 in NK/T cell lymphoma from Northern China.

Authors:  Lingling Sun; Kui Che; Zhenzhen Zhao; Song Liu; Xiaoming Xing; Bing Luo
Journal:  Virol J       Date:  2015-09-04       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.